Trintellix (Vortioxetine hydrobromide), formerly sold under the name Brintellix, is an antidepressant that was jointly developed by the pharmaceutical companies Lundbeck and Takeda. In 2013, Trintellix received FDA approval for the treatment of major depressive disorder in the United States. Trintellix is classified as a “serotonin modulator and stimulator” in that it functions as an …
Coffee is a brewed drink prepared from the roasting of coffee beans, which technically, are seeds of berries produced by the Coffea plant. Specifically, when Coffea plant berries ripen, they are picked, processed, dried, roasted, ground, brewed with boiling water, and served as the beverage we’ve come to know as coffee. Although the Coffea plant …
Niacin (vitamin B3), also referred to as nicotinic acid, is a human nutrient that functions as a precursor to NAD (nicotinamide adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate). NAD is a coenzyme recognized for its involvement in the catabolism of fats, carbohydrates, and proteins, as well as sending signals for DNA repair. NADP is …
Belviq (Lorcaserin) is an anorectic medication manufactured by Arena Pharmaceuticals for the long-term management of obesity. As of 2012, the FDA approved lorcaserin to promote weight loss in adults with: BMIs exceeding 30 or BMIs exceeding 27 plus [at least] one weight-related medical comorbidity such as diabetes, hyperlipidemia, and/or hypertension. Upon administration, lorcaserin functions primarily …
Phentermine is an anorectic medication utilized principally for the short-term treatment of obesity as an adjunct to caloric restriction, dietary modifications, and physical exercise. It is formally classified as a psychostimulant due to the fact that it increases mental and physical arousal [via sympathomimetic mechanisms]. Specifically, phentermine facilitates central and peripheral catecholamine release (primarily of …
Qsymia is a weight loss drug engineered by the California-based pharmaceutical company Vivus Inc. It was initially approved by the FDA in 2012 for weight reduction among adults with BMIs (body mass indexes) exceeding 30 kg/m² as an adjunct to interventions such as caloric restriction, dietary modification, and regular exercise. Qsymia is also approved for …
Data from the CDC (Centers for Disease Control) indicates that approximately 78.6 million adults (34.9%) are clinically obese. Healthcare costs of obesity-related medical conditions such as: cardiovascular disease, cancers, diabetes, and stroke (to name a few) – are thought to exceed $190 billion per year, accounting for over one-fifth of all annual medical expenses in …